PGNY:NASDAQ
Progyny Inc
$27.84
arrow_upward
+1.64%(+0.45) 1D
$27.70
arrow_downward
-0.50% (-0.14)bedtimeAfter hours
Closed: Oct 14, 4:00:00 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PGNY...
Open
$27.26
High
$28.06
Low
$27.26
Mkt. cap
2.14B
Avg. vol.
1.18M
Volume
0.00
P/E ratio
30.26
52-wk high
$33.05
52-wk low
$16.10
EPS
$0.92
Beta
1.02
Shares outstanding
76.73M
No. of employees
846
Open
$27.26
High
$28.06
Low
$27.26
Mkt. cap
2.14B
Avg. vol.
1.18M
Volume
0.00
P/E ratio
30.26
52-wk high
$33.05
52-wk low
$16.10
EPS
$0.92
Beta
1.02
Shares outstanding
76.73M
No. of employees
846
News stories
From web sources and news partners
Yahoo Finance
·
10 hours ago
Progyny, Inc. (PGNY) Stock Forecasts
Investing.com South Africa
·
15 hours ago
Form 144 Progyny For: 14 October By Investing.com
Stock Titan
·
16 hours ago
A $52,612 sale of 1,879 shares is proposed at Progyny (PGNY) by officer Melissa B. Cummings.
Profile
Progyny, Inc. is an American benefits-management company that administers employer-sponsored fertility, family-building and women's-health benefits. The company began offering fertility benefits in 2016. It completed an initial public offering on the Nasdaq in 2019. In 2024, it was described as a pioneer in the field and the only publicly traded fertility-benefits company in the United States.
Progyny's services include fertility-treatment benefits, a network of health-care providers, patient-support services and the Progyny Rx pharmacy-benefits program. The company is headquartered in New York City. Wikipedia
About Progyny Inc
CEOPeter Anevski
Employees846
FoundedApr 3, 2008
Headquarters-
SectorHealth care provider
Websiteprogyny.com
Analyst ratings
Based on 10 analysts giving stock ratings to PGNY in the past 3 months
Strong buy
Buy
8
Hold
2
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for PGNY in the last 3 months.
Highest
Current $27.84
$40.00 (+43.68%)
Average
$33.67 (+20.94%)
Lowest
$30.00 (+7.76%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Peter Warendorf Barclays | Hold | Maintained | $30.00 | +7.8% | 10/15/2026 |
Richard Close Canaccord Genuity | Buy | Reiterated | $35.00 | +25.7% | 10/08/2026 |
Michael Cherny Leerink Partners | Buy | Maintained | - | - | 10/07/2026 |
Constantine Davides Citizens JMP | Buy | Maintained | $33.00 | +18.5% | 09/08/2026 |
Lisa Gill J.P. Morgan | Hold | Maintained | $30.00 | +7.8% | 08/21/2026 |
Stan Berenshteyn Wells Fargo | Buy | Initiated | $37.00 | +32.9% | 08/20/2026 |
Jailendra Singh Truist Financial | Buy | Reiterated | $36.00 | +29.3% | 08/13/2026 |
Sarah James Cantor Fitzgerald | Buy | Reiterated | $31.00 | +11.4% | 08/06/2026 |
Allen Lutz Bank of America Securities | Buy | Reiterated | $31.00 | +11.4% | 08/07/2026 |
David Larsen BTIG | Buy | Maintained | $40.00 | +43.7% | 07/24/2026 |
Scott Schoenhaus KeyBanc | Buy | Maintained | $35.00 | +25.7% | 07/13/2026 |
Unknown Analyst Goldman Sachs | Buy | Upgraded | $30.00 | +7.8% | 05/19/2026 |
Last report
Aug 6, 2026
Fiscal period
Q2 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.55 / $0.52
+6.16%beat
arrow_upward
Revenue / Est. (USD)
350.51M / 346.25M
+1.23%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 313.35M | 318.40M | 328.50M | 350.51M |
Cost of goods sold | 240.51M | 241.52M | 245.43M | 261.21M |
Cost of revenue | 240.51M | 241.52M | 245.43M | 261.21M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 51.31M | 53.96M | 47.69M | 49.30M |
Operating expense | 51.31M | 53.96M | 47.69M | 49.30M |
Total operating expenses | 291.82M | 295.48M | 293.12M | 310.51M |
Operating income | 21.53M | 22.92M | 35.38M | 40.00M |
Other non operating income | - | - | - | - |
EBT including unusual items | 23.96M | 17.85M | 36.88M | 41.14M |
EBT excluding unusual items | 23.96M | 25.55M | 36.83M | 41.14M |
Income tax expense | 10.10M | 5.37M | 12.65M | 13.08M |
Effective tax rate | 42.15% | 30.07% | 34.30% | 31.81% |
Other operating expenses | - | - | - | - |
Net income | 13.86M | 12.48M | 24.23M | 28.05M |
Net profit margin | 4.42% | 3.92% | 7.38% | 8.00% |
Earnings per share | 0.45 | 0.48 | 0.50 | 0.55 |
Interest and investment income | 2.44M | 2.63M | 1.45M | 1.13M |
Interest expense | - | - | - | - |
Net interest expenses | 2.44M | 2.63M | 1.45M | 1.13M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 22.80M | 24.29M | 36.86M | 41.63M |
Gain or loss from assets sale | - | - | 52.00K | 528.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1